{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:02:27Z","timestamp":1782903747006,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T00:00:00Z","timestamp":1534809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"publisher","award":["Fondi di Ateneo"],"award-info":[{"award-number":["Fondi di Ateneo"]}],"id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40618-018-0943-8","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T23:41:45Z","timestamp":1534808505000},"page":"471-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves\u2019 disease and Graves\u2019 orbitopathy"],"prefix":"10.1007","volume":"42","author":[{"given":"M.","family":"Marin\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rotondo Dottore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ionni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lanzolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sabini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sframeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Menconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Latrofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Marcocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chiovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"943_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves\u2019 Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association\/European Group on Graves\u2019 orbitopathy guidelines for the management of Graves\u2019 orbitopathy. Eur Thyroid J 5:9\u201326","journal-title":"Eur Thyroid J"},{"key":"943_CR2","first-page":"444","volume":"36","author":"E Piantanida","year":"2013","unstructured":"Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves\u2019 orbitopathy in the XXI century. J Endocrinol Investig 36:444\u2013449","journal-title":"J Endocrinol Investig"},{"key":"943_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/thy.2014.0475","volume":"25","author":"M Leo","year":"2015","unstructured":"Leo M, Menconi F, Rocchi R, Latrofa F, Sisti E, Profilo MA, Mazzi B, Albano E, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2015) Role of the underlying thyroid disease on the phenotype of Graves\u2019 orbitopathy in a tertiary referral center. Thyroid 25:347\u2013351","journal-title":"Thyroid"},{"key":"943_CR4","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1055\/s-0035-1555762","volume":"47","author":"RS Bahn","year":"2015","unstructured":"Bahn RS (2015) Current insights into the pathogenesis of Graves\u2019 ophthalmopathy. Horm Metab Res 47:773\u2013778","journal-title":"Horm Metab Res"},{"key":"943_CR5","doi-asserted-by":"publisher","first-page":"T29","DOI":"10.1530\/JME-17-0276","volume":"61","author":"M Mohyi","year":"2018","unstructured":"Mohyi M, Smith TJ (2018) IGF-I receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol 61:T29\u2013T43","journal-title":"J Mol Endocrinol"},{"key":"943_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.beem.2011.10.002","volume":"26","author":"TJ Smith","year":"2012","unstructured":"Smith TJ, Heged\u00fcs L, Douglas RS (2012) Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves\u2019 orbitopathy. Best Pract Res Clin Endocrinol Metab 26:291\u2013302","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"943_CR7","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J Immunol 181:4397\u20134405","journal-title":"J Immunol"},{"key":"943_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1089\/thy.2007.0404","volume":"18","author":"TJ Smith","year":"2008","unstructured":"Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG (2008) Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 18:983\u2013988","journal-title":"Thyroid"},{"key":"943_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/08916939309014643","volume":"16","author":"DR Weightman","year":"1993","unstructured":"Weightman DR, Perros P, Sherif IH, Kendall-Taylor P (1993) Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 16:251\u2013577","journal-title":"Autoimmunity"},{"key":"943_CR10","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4049\/jimmunol.168.2.942","volume":"168","author":"J Pritchard","year":"2002","unstructured":"Pritchard J, Horst N, Cruikshank W, Smith TJ (2002) Igs from patients with Graves\u2019 disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 168:942\u2013950","journal-title":"J Immunol"},{"key":"943_CR11","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ (2003) Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 170:6348\u20136354","journal-title":"J Immunol"},{"key":"943_CR12","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1210\/jc.2016-1315","volume":"101","author":"CC Krieger","year":"2016","unstructured":"Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC (2016) TSH\/IGF-1 receptor cross talk in Graves\u2019 ophthalmopathy pathogenesis. J Clin Endocrinol Metab 101:2340\u20132347","journal-title":"J Clin Endocrinol Metab"},{"key":"943_CR13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1210\/jc.2012-1771","volume":"98","author":"WB Minich","year":"2013","unstructured":"Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, K\u00f6hrle J, Eckstein A, Schomburg L (2013) Autoantibodies to the IGF1 receptor in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 98:752\u2013760","journal-title":"J Clin Endocrinol Metab"},{"key":"943_CR14","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1210\/jc.2011-0307","volume":"96","author":"WM Wiersinga","year":"2011","unstructured":"Wiersinga WM (2011) Autoimmunity in Graves\u2019 ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 96:2386\u20132394","journal-title":"J Clin Endocrinol Metab"},{"key":"943_CR15","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/thy.2017.0105","volume":"27","author":"CC Krieger","year":"2017","unstructured":"Krieger CC, Neumann S, Marcus-Samuels B, Gershengorn MC (2017) TSHR\/IGF-1R cross-talk, not IGF-1R stimulating antibodies, mediates Graves\u2019 ophthalmopathy pathogenesis. Thyroid 27:746\u2013747","journal-title":"Thyroid"},{"key":"943_CR16","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1089\/thy.2017.0281","volume":"27","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Janssen JAMJL et al (2017) Response to Krieger et al. Re: \u201cTSHR\/IGF-1R cross-talk, not IGF-1R stimulating antibodies, mediates Graves\u2019 ophthalmopathy pathogenesis\u201d (Thyroid 2017;27:746\u2013747). Thyroid 27:1458\u20131459","journal-title":"Thyroid"},{"key":"943_CR17","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/thy.2017.0472","volume":"27","author":"S Neumann","year":"2017","unstructured":"Neumann S, Gershengorn MC (2017) Rebuttal to Smith and Janssen. Thyroid 27:746\u2013747. \n                    https:\/\/doi.org\/10.1089\/thy.2017.0281\n                    \n                  \n                           (1459\u20131460)","journal-title":"Thyroid"},{"key":"943_CR18","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1089\/thy.2018.0089","volume":"28","author":"B Marcus-Samuels","year":"2018","unstructured":"Marcus-Samuels B, Krieger CC, Boutin A, Kahaly G, Neumann S, Gershengorn MC (2018) Evidence that Graves\u2019 ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors. Thyroid 28:650\u2013655","journal-title":"Thyroid"},{"key":"943_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1210\/jc.2012-2270","volume":"98","author":"AJ Varewijck","year":"2013","unstructured":"Varewijck AJ, Boelen A, Lamberts SW, Fliers E, Hofland LJ, Wiersinga WM, Janssen JA (2013) Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 98:769\u2013776","journal-title":"J Clin Endocrinol Metab"},{"key":"943_CR20","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748\u20131761","journal-title":"N Engl J Med"},{"key":"943_CR21","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40618-017-0717-8","volume":"40","author":"E Piantanida","year":"2017","unstructured":"Piantanida E, Bartalena L (2017) Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves\u2019 orbitopathy? J Endocrinol Invest 40:885\u2013887","journal-title":"J Endocrinol Invest"},{"key":"943_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40618-017-0608-z","volume":"40","author":"L Bartalena","year":"2017","unstructured":"Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marin\u00f2 M, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Curr\u00f2 N, Boschi A, Bernard M, von Arx G, Perros P, Kahaly GJ (2017) Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves\u2019 orbitopathy? J Endocrinol Investig 40:547\u2013553","journal-title":"J Endocrinol Investig"},{"key":"943_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamaophthalmol.2018.0806","volume":"136","author":"G Rotondo Dottore","year":"2018","unstructured":"Rotondo Dottore G, Torregrossa L, Caturegli P, Ionni I, Sframeli A, Sabini E, Menconi F, Piaggi P, Sellari-Franceschini S, Nardi M, Latrofa F, Vitti P, Marcocci C, Basolo F, Marin\u00f2 M (2018) Association of T and B cells infiltrating orbital tissues in Graves orbitopathy with Graves orbitopathy activity. A possible explanation for GO response to immunosuppressive treatments. JAMA Ophthalmol 136:613\u2013619","journal-title":"JAMA Ophthalmol"},{"key":"943_CR24","doi-asserted-by":"crossref","unstructured":"Sellari-Franceschini S, Rocchi R, Marin\u00f2 M, Bajraktari A, Mazzi B, Fiacchini G, Lepri P, Dallan I, Vitti P, Marcocci C (2018) Rehabilitative orbital decompression for Graves\u2019 orbitopathy: results of a randomized clinical trial. J Endocrinol Investig (in press)","DOI":"10.1007\/s40618-018-0847-7"},{"key":"943_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, K\u00f6nig J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, F\u00fchrer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marin\u00f2 M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM, European Group on Graves\u2019 Orbitopathy (EUGOGO) (2018) Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves\u2019 orbitopathy\u2014a randomized, observer blind, multicenter trial. Lancet Diabetes Endocrinol 6:287\u2013298","journal-title":"Lancet Diabetes Endocrinol"},{"key":"943_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1089\/thy.2012.0379","volume":"23","author":"MA Profilo","year":"2013","unstructured":"Profilo MA, Sisti E, Marcocci C, Vitti P, Pinchera A, Nardi M, Rocchi R, Latrofa F, Menconi F, Altea MA, Leo M, Rago T, Marin\u00f2 M (2013) Thyroid volume and severity of Graves\u2019 orbitopathy. Thyroid 23:97\u2013102","journal-title":"Thyroid"},{"key":"943_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1089\/thy.2017.0430","volume":"28","author":"E Sabini","year":"2018","unstructured":"Sabini E, Mazzi B, Profilo MA, Mautone T, Casini G, Rocchi R, Ionni I, Menconi F, Leo M, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2018) Serum high cholesterol is a novel risk factor for Graves\u2019 orbitopathy (GO): results of a cross-sectional study. Thyroid 28:386\u2013394","journal-title":"Thyroid"},{"key":"943_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/01676830490504089","volume":"23","author":"MP Mourits","year":"2004","unstructured":"Mourits MP, Lombardo SH, van der Sluijs FA, Fenton S (2004) Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves\u2019 patients. An exploratory study. Orbit 23:161\u2013168","journal-title":"Orbit"},{"key":"943_CR29","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1089\/thy.2006.0279","volume":"17","author":"H Bilen","year":"2007","unstructured":"Bilen H, Gullulu G, Akcay G (2007) Exophthalmometric values in a normal Turkish population living in the northeastern part of Turkey. Thyroid 17:525\u2013528","journal-title":"Thyroid"},{"key":"943_CR30","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1097\/OPX.0b013e3181890dc7","volume":"85","author":"MB Kashkouli","year":"2008","unstructured":"Kashkouli MB, Nojomi M, Parvaresh MM, Sanjari MS, Modarres M, Noorani MM (2008) Normal values of Hertel exophthalmometry in children, teenagers, and adults from Tehran, Iran. Optom Vis Sci 85:1012\u20131017","journal-title":"Optom Vis Sci"},{"key":"943_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/112067210801800201","volume":"18","author":"U Beden","year":"2008","unstructured":"Beden U, Ozarslan Y, Ozt\u00fcrk HE, S\u00f6nmez B, Erkan D, Oge I (2008) Exophthalmometry values of Turkish adult population and the effect of age, sex, refractive status, and Hertel base values on Hertel readings. Eur J Ophthalmol 18:165\u2013171","journal-title":"Eur J Ophthalmol"},{"key":"943_CR32","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1442-9071.2009.02087.x","volume":"37","author":"W Chan","year":"2009","unstructured":"Chan W, Madge SN, Senaratne T, Senanayake S, Edussuriya K, Selva D, Casson RJ (2009) Exophthalmometric values and their biometric correlates: the Kandy Eye Study. Clin Exp Ophthalmol 37:496\u2013502","journal-title":"Clin Exp Ophthalmol"},{"key":"943_CR33","first-page":"360","volume-title":"Werner and Ingbar\u2019s the thyroid: a fundamental and clinical text","author":"C Marcocci","year":"2005","unstructured":"Marcocci C, Marin\u00f2 M (2005) Thyroid directed antibodies. In: Braverman LE, Utiger RD (eds) Werner and Ingbar\u2019s the thyroid: a fundamental and clinical text, 9th edn. Lippincott, Williams & Wilkins, Philadelphia, pp 360\u2013372","edition":"9"},{"key":"943_CR34","doi-asserted-by":"publisher","first-page":"E44","DOI":"10.1210\/jc.2011-2077","volume":"97","author":"M Leo","year":"2012","unstructured":"Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzi B, Sisti E, Profilo MA, Marin\u00f2 M (2012) Outcome of Graves\u2019 orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 97:E44\u201348","journal-title":"J Clin Endocrinol Metab"},{"key":"943_CR35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40618-015-0255-1","volume":"38","author":"F Menconi","year":"2015","unstructured":"Menconi F, Leo M, Vitti P, Marcocci C, Marin\u00f2 M (2015) Thyroid ablation in Graves\u2019 orbitopathy. J Endocrinol Investig 38:809\u2013815","journal-title":"J Endocrinol Investig"},{"key":"943_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","volume":"12","author":"P Perros","year":"2017","unstructured":"Perros P, Heged\u00fcs L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, Salvi M, Lazarus JH, Eckstein A, Pitz S, Boboridis K, Anagnostis P, Ayvaz G, Boschi A, Brix TH, Curr\u00f2 N, Konuk O, Marin\u00f2 M, Mitchell AL, Stankovic B, T\u00f6r\u00fcner FB, von Arx G, Zarkovi\u0107 M, Wiersinga WM (2017) Graves\u2019 orbitopathy as a rare disease in Europe: a European Group On Graves\u2019 Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12:72","journal-title":"Orphanet J Rare Dis"},{"key":"943_CR37","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1210\/jc.2005-2813","volume":"91","author":"AK Eckstein","year":"2006","unstructured":"Eckstein AK, Plicht M, Lax H, Neuh\u00e4user M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464\u20133470","journal-title":"J Clin Endocrinol Metab"},{"key":"943_CR38","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40618-015-0241-7","volume":"38","author":"E Sisti","year":"2015","unstructured":"Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2015) Long-term outcome of Graves\u2019 orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Investig 38:661\u2013668","journal-title":"J Endocrinol Investig"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0943-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-018-0943-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0943-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T19:08:08Z","timestamp":1568747288000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-018-0943-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1007\/s40618-018-0943-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,21]]},"assertion":[{"value":"26 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All diagnostic and therapeutic procedures performed in this study were in accordance with ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the local Ethic Committee (Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana; approval number: 13354_MARINO\u2019).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the individual participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}